Search results

...discovered and it is not that surprising considering the properties of the binding site: ...ed [[aromatic]] [[side chain]]s for achieving high affinity small molecule binding. ...

...discovered and it is not that surprising considering the properties of the binding site: ...ed [[aromatic]] [[side chain]]s for achieving high affinity small molecule binding. ...

...se site. The other force is the binding of the aglycone, which affects the binding affinity of the entire inhibitor. The discovery of T-1095 led to an investigation of how to enhance potency, selectivity and oral bioavailability by adding various substituents to the glycoside co ...

...se site. The other force is the binding of the aglycone, which affects the binding affinity of the entire inhibitor. The discovery of T-1095 led to an investigation of how to enhance potency, selectivity and oral bioavailability by adding various substituents to the glycoside co ...

...intermediate class between phenylalkylamine and dihydropyridines in their selectivity for vascular calcium channels. By having both cardiac depressant and vasodi ...ependently to the channel, expressing [[cooperative binding|noncooperative binding]]. Early studies showed a link between calcium and the release of [[vasopre ...

...anism as a prodiuretic with great promise. However, it has been shown that binding of different sugars to the glucose site affects the orientation of the [[ag The [[elimination half-life]], [[bioavailability]], [[protein binding]], the blood concentration [[Cmax (pharmacology)|Cmax]] at time tmax, and o ...

...intermediate class between phenylalkylamine and dihydropyridines in their selectivity for vascular calcium channels. By having both cardiac depressant and vasodi ...ependently to the channel, expressing [[cooperative binding|noncooperative binding]]. Early studies showed a link between calcium and the release of [[vasopre ...

...anism as a prodiuretic with great promise. However, it has been shown that binding of different sugars to the glucose site affects the orientation of the [[ag The [[elimination half-life]], [[bioavailability]], [[protein binding]], the blood concentration [[Cmax (pharmacology)|Cmax]] at time tmax, and o ...

現代の創薬では、[[Affinity (pharmacology)#Protein-ligand binding/ja|親和性]]、[[binding selectivity/ja|選択性]]（副作用の可能性を減らす）、有効性／[[potency (pharmacology)/ja|効力]]、[[Metabolism/ja| ...

...ty (pharmacology)#Protein-ligand binding|affinity]], [[binding selectivity|selectivity]] (to reduce the potential of side effects), efficacy/[[potency (pharmacolo ...re usually much smaller, and they bind to the target protein with weaker [[binding affinity]] than hits that are identified from HTS. Further modifications th ...

...ty (pharmacology)#Protein-ligand binding|affinity]], [[binding selectivity|selectivity]] (to reduce the potential of side effects), efficacy/[[potency (pharmacolo ...

...ty (pharmacology)#Protein-ligand binding|affinity]], [[binding selectivity|selectivity]] (to reduce the potential of side effects), efficacy/[[potency (pharmacolo ...